- SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor
- How Good Are You As A Golfer?
- Your Secret Wealth Creation Strategy – OPT?
- U.S. Auto Manufacturers Are They Ready To Declare Bankruptcy?
- How to Get Your Prospects Beg You to Accept their Money?
- Negative Thinking Robbing Souls of Inner Peace
- Understanding Local Car Auctions
- 4 Amazing Ways Viral Marketing Will Work for Your Site
- How To Overcome Your Troubles
- How to Make a Difference Every Day
pharmaceuticals
SGX Pharmaceuticals Announces Strategic Collaboration To Develop And Commercialize BCR-ABL Inhibitor
Under the terms of the agreement, SGX will receive from Novartis $25 million in upfront payments and the purchase of SGX common stock. Along with success-based milestones, but excluding royalties, total payments to SGX could exceed $515 million, including a minimum of two years of research funding. The success of Gleevec(TM) (imatinib), the first targeted [...]